Tracheobronchial granular cell myoblastoma (GCM) is rare. Although the tumor has some malignant properties, it is considered benign, and there is no consensus regarding treatment. Three cases are reported here. Bronchoscopic treatment in patients with GCM may be attempted as a first approach in case the tumor is intraluminal.
INTRODUCTION
The first report on granular cell myoblastoma (GCM) was by Abrikossoff in 1926 and heralded a considerable quantity ofcase reports, reviews, and histologic investigations. Frenckner, in 1938, described the first GCM in the respiratory tract. Since then, more than 60 cases have been reported (1) . Multicentric tracheobronchial localization of GCM has also been described (2, 3) . GCM is characterized macroscopically by a relative small size, usually less than 5 cm in diameter, ill-defined margins, lack of encapsulation, firm texture, and yellowish or greyish color (4, 5) . The tumor appears to infiltrate into the surrounding tissue, causing a rather characteristic pseudo-epitheliomatous hyperplasia of the overlying epithelium. Microscopy 
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Review of the literature on the treatment of this benign tumor showed that there is no consensus regarding treatment (1, 4) . Surgery has been advocated as the treatment of choice (6) . Others favored local treatment of GCM (4 A 36-year-old Caucasian woman had a history of "bronchitis" during infancy. For several months she had been complaining of shortness of breath and cough, which persisted despite treatment with inhaled steroids and 12-agonists. Bronchoscopy was performed and a 1.5 by 2 cm yellow tumor 4 cm above the carina in the membranous part of the trachea was found. Histologic examination revealed granular cell myoblastoma.
The patient was referred to our hospital for further treatment. Physical examination, laboratory results, and chest x-rays were normal. High-resolution computed tomography (HRCT) of the thorax showed nonspecific changes of the right and left lower lobe in the parenchymal setting. A 2-cm lesion with possible tumor extension dorsal in the trachea was seen on the magnetic resonance imaging (MRI) scan. Because of tumor size and location, partial tracheal resection and tracheoplasty were performed and the anastomosis was covered with a pericardial patch. The margins ofthe resected specimen were not free from tumor microscopically. The postsurgical period was complicated by mediastinitis and anastomotic dehiscence. The pericardial patch loosened and had to be removed bronchoscopically because of airway obstruction. Despite microscopic residual disease, the patient is doing well without local recurrence for a follow-up period of 2 years. CT scan and bronchoscopy were repeatedly negative for recurrent disease.
aspirated barley-corn in the bronchus intermedius. The latter was easily removed.
On histologic examination the tracheobronchial lesion was a GCM (Fig. 2A) (Fig. 1A) . Biopsy revealed GCM. HRCT did not show tumor extension pedbronchially, and no enlarged lymph nodes were found. Bronchoscopic electrosurgery was performed using the argon beam coagulation technique under local anesthesia (Fig. 1B) . Follow-up has been uneventful, and she is still free of disease after 1 year. Repeated bronchoscopic examination was negative for GCM (Fig. 1C) . In a review of 13 cases of bronchoscopic removal of GCM, resection was advocated for tumors larger than 8 mm, and in patients with irreversible damage of the pulmonary parenchyma distal to the lesion (6) . Bronchoscopic therapy was considered as a treatment alternative if tumor size was less than 8 mm, or if major surgery was contraindicated. Multicentric lesions less than 10 mm should be removed bronchoscopically, and those larger than 10 mm surgically (lobectomy, pneumonectomy, or bronchoplasty). HRCT may be useful in determining tumor extent in cases ofintraluminal tumors (9, 10) and in assessing the quality ofpulmonary parenchyma distal to the lesion (11) .
The finding of tumor extension is important as bronchoscopic treatment is only potentially curative in tumors not extending to the bronchial mucosal layers. This was particularly true in patients with superficial squamous cell lung cancer. Whether the same situation may apply to GCM is unknown ( 12, 13) .
Successful local therapy of GCM using the CO2 laser, the Nd-YAG laser, and endobronchial curettage have been reported (4, 8, 14) . However, a report of recurrent disease 5 months after CO2 laser therapy of a 2 by cm large tracheal lesion has also been published (1) all our patients, the tumor proved to be strictly intraluminal, and the MRI findings for the first patient were falsepositive. Tracheoplasty in our first patient was complicated by mediastinitis and despite microscopic residual disease, recurrence has not occurred. This seems to fit with GCM characteristics of a more benign nature in the tracheobronchial tree in contrast to rare malignant forms as have been described in other organs (15 (17, 18) .
Recurrent GCMs were was probably due to inadequate assessment of peribronchial tumor extension before treatment.
The morbidity of bronchoscopic treatment is low, so bronchoscopic therapy should be attempted first in patients with intraluminal lesions. This is in accordance with several other reports published previously, justifying a more conservative approach toward tracheobronchial GCM, even if localizations are multiple (4, 6, 8) .
In summary, bronchoscopic treatment of GCM may be attempted as the first approach for intraluminal lesions not larger than 1 cm without peribronchial growth and in the absence of irreversible damage of lung parenchyma.
